3/5/2010

The House Energy and Commerce Committee scheduled a hearing Wednesday to look into the FDA's drug-safety efforts amid criticism that the agency is slow to respond to reports of adverse reactions to approved treatments. Deputy FDA Commissioner Joshua Sharfstein will appear before a health subcommittee as part of the inquiry.

Full Story:
Reuters

Related Summaries